Motor Unit Number Estimation (MUNE): pro

Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial

In November 2002, an advisory board meeting was convened by Novartis Pharma to provide recommendations and rationale for clinical trials designed to evaluate new treatments, such as TCH346, for amyotrophic lateral sclerosis (ALS). In terms of selecting appropriate outcome measures, the panel recommended the use of the ALS Functional Rating Scale (ALSFRS-R) to measure primary endpoints. A review of other key issues in this area including regional variations in the epidemiology, diagnosis and management of ALS, defining patient populations and doses of trial medication, and accommodating the likelihood of co-medication with pre-existing treatment in trial design, are discussed.

Number of Edb motor units estimated using an adapted multiple point stimulation method: normal values and longitudinal studies in ALS and peripheral neuropathies

OBJECTIVE

To validate the adapted multiple point stimulation (AMPS) method to estimate the number of motor units (MUNE) from the extensor digitorum brevis (Edb) muscle.

METHODS

Twenty controls (10 young and 10 old) were examined on both sides and 10 patients with amyotrophic lateral sclerosis (ALS) and 5 with acute peripheral neuropathy (PN) were examined longitudinally on one side during a series of repeated electrophysiological sessions.

RESULTS

In the controls, the median MUNE and size of the motor unit action potentials (S-MUAPs) were found to be age-related (411 and 70 microVms in the young group; 164 and 142 microVms in the old group; P < 0.01), with a coefficient of variation of MUNE values of 27% and 20%, respectively. In the ALS group, the median MUNE value at diagnosis was 31 (P < 0.05 vs. controls), and during a mean follow-up period of 11.5 months a continuous decrease in the MUNE value was seen, together with an initial increase, followed by a later decrease in 4 cases, in S-MUAP size. In the PN group, the MUNE value was initially similar to that in controls, but then decreased, accompanied by an increase in S-MUAP size, and then showed a progressive increase, together with a decrease in S-MUAP size.

CONCLUSIONS

AMPS, a MUNE method developed in the upper extremity, also appears to be a useful procedure for quantifying changes in the MUNE value in the Edb muscle without specific software in order to study age-related changes or changes in patients with ALS or PN.

Proposed modification to data analysis for statistical motor unit number estimate

Motor unit number estimation (MUNE) is an important electrophysiological technique for quantitative measurement of motor neuron loss. Although commonly used, there is no consensus concerning the optimal procedure for statistical MUNE, particularly regarding several operator-dependent variables. To assess the variables, we analyzed 500 sequential, submaximal compound muscle action potential (CMAP) responses at three or four stimulus intensities in 10 controls and 10 patients with amyotrophic lateral sclerosis (ALS). In both controls and ALS patients, we found that posttest filtering data based on 20% or 25% windows or 2, 2.5, or 3 SD excludes <5% of data. Windows of 10% or 15% excluded <5% of data in controls but not in ALS patients. Excluding data based on +/-2 SD, the coefficient of variation for final MUNE was 12% in controls and 6% in ALS patients. Group sizes of 30 or 50 and sample sizes of 300 to 500 sequential CMAP responses per run yielded the lowest coefficient of variation. We propose that statistical MUNE data should be analyzed based on excluding data >2 SD from the mean, because this is operator independent, includes the majority of data, effectively excludes clearly outlying data, such as fasciculations or movement artifact, and has a reasonable coefficient of variation.